Vol.

No.

June 05, 2020Jun 05, 2020

Free

DOWNLOAD THE PDF

I could have been George Floyd—many times Reflecting on the cancer of racism

Cover Story

Free Guest Editorial

I could have been George Floyd—many times

Reflecting on the cancer of racism

By Robert A. Winn

I am almost certain that no other director of an NCI-designated cancer center can claim the distinction of having had a gun pulled on them by police.

Free Guest Editorial

I could have been George Floyd, too

By Otis W. Brawley

Free

Here's what cancer groups say about police brutality and health disparities

Editorial Free

What We Believe

By Alexandria Carolan, Katie Goldberg, Matthew Bin Han Ong and Paul Goldberg

Conversation with The Cancer Letter Free

States with Medicaid expansion have lower overall cancer mortality, study finds
No additional decrease observed in black populations because of worse baseline

By Matthew Bin Han Ong

Conversation with The Cancer Letter COVID-19 & Cancer Free

Clifford Hudis: What a virtual meeting can accomplish—and what a virtual meeting cannot accomplish

By Paul Goldberg

Free Guest Editorial

Fostering a culture of gender-based respect and inclusion in oncology

By Narjust Florez, Christina Chapman, Stephanie L. Graff, Tatiana M. Prowell and Miriam A. Knoll

COVID-19 & Cancer Free Guest Editorial

ASCO data will provide actionable insights from the COVID-19 pandemic—for every patient

By Richard L. Schilsky

COVID-19 Updates

FDA publicly shares antibody test performance data from kits as part of validation study

In Brief

Richard L. Schilsky, chief medical officer of ASCO, to retire in February

CancerLinQ Discovery platform offers access to real-world cancer data

David Rivadeneira named director of Northwell Health Cancer Institute at Huntington

MD Anderson, Rakuten Medical collaborate to advance Illuminox platform for cancer treatments

Clinical Roundup

ACS study defines lost earnings for black cancer patients

Keytruda monotherapy significantly reduces risk of disease progression, death in colorectal cancer

Alecensa increases OS rate in ALK-positive NSCLC

Xtandi significantly extends OS in men with non-metastatic CRPC

Drugs & Targets

Atezolizumab + bevacizumab approved by FDA for unresectable HCC

Ramucirumab + erlotinib approved by FDA for first-line metastatic NSCLC

Piqray receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation

Sarclisa approved by European Commission for adults with relapsed and refractory multiple myeloma

Subcutaneous formulation of Darzalex approved by EC for multiple myeloma

NCI Trials

NCI Trials for June 2020

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

PREVIOUS ISSUE

NEXT ISSUE

I could have been George Floyd—many times

I could have been George Floyd, too

Here's what cancer groups say about police brutality and health disparities

What We Believe

States with Medicaid expansion have lower overall cancer mortality, study finds
No additional decrease observed in black populations because of worse baseline

Clifford Hudis: What a virtual meeting can accomplish—and what a virtual meeting cannot accomplish

Fostering a culture of gender-based respect and inclusion in oncology

ASCO data will provide actionable insights from the COVID-19 pandemic—for every patient

COVID-19 Updates

FDA publicly shares antibody test performance data from kits as part of validation study

In Brief

Richard L. Schilsky, chief medical officer of ASCO, to retire in February

CancerLinQ Discovery platform offers access to real-world cancer data

David Rivadeneira named director of Northwell Health Cancer Institute at Huntington

MD Anderson, Rakuten Medical collaborate to advance Illuminox platform for cancer treatments

Clinical Roundup

ACS study defines lost earnings for black cancer patients

Keytruda monotherapy significantly reduces risk of disease progression, death in colorectal cancer

Alecensa increases OS rate in ALK-positive NSCLC

Xtandi significantly extends OS in men with non-metastatic CRPC

Drugs & Targets

Atezolizumab + bevacizumab approved by FDA for unresectable HCC

Ramucirumab + erlotinib approved by FDA for first-line metastatic NSCLC

Piqray receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation

Sarclisa approved by European Commission for adults with relapsed and refractory multiple myeloma

Subcutaneous formulation of Darzalex approved by EC for multiple myeloma

NCI Trials

NCI Trials for June 2020

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login